INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 49m ago
HOUSE PTR9m ago
SEC 13F9m ago
ROBINHOOD CHAIN8m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

O'Day Daniel Patrick sold GILD

Director, Chairman & CEO · GILEAD SCIENCES, INC. · Common Stock

Side
SELL
Value
$15.61M
Shares
115.6K
Price
$135
Executed
Jan 23, 2026
Disclosed
Jan 26, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Jan 23 executedJan 26, 2026 disclosed

GILD · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
27/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+17 / 25

    $15.6M reported value · 16.9% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · GILD

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    7
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Open-market sale · 10b5-1 plan
    		SELL$469K
    3,000 sh
    		Oct 15, 2026Oct 16, 2026
    traded Oct 15, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BE
    Burkhart ErinSVP, Controllership
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,223 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    17
    BE
    Burkhart ErinSVP, Controllership
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,223 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    24
    BE
    Burkhart ErinSVP, Controllership
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$117K
    768 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    5
    OP
    O'Day Daniel PatrickDirector, Chairman & CEO
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    8,780 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Berger DietmarChief Medical Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    533 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Berger DietmarChief Medical Officer
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$38K
    263 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Berger DietmarChief Medical Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    533 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,797 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    8
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$195K
    1,347 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    5
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,797 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    13
    CM
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    590 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CM
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    590 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    OP
    O'Day Daniel PatrickDirector, Chairman & CEO
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    8,780 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CM
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$41K
    285 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    11
    OP
    O'Day Daniel PatrickDirector, Chairman & CEO
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$613K
    4,230 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    8
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Open-market sale · 10b5-1 plan
    		SELL$167K
    1,165 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    2
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Option exercise · 10b5-1 plan
    		M$79K
    1,165 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    2
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Option exercise · 10b5-1 plan
    		M$122K
    1,816 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    11
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Open-market sale · 10b5-1 plan
    		SELL$263K
    1,816 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001638643-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 23, 2026
    Published
    Jan 26, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    O'Day Daniel Patrick
    Role
    Director, Chairman & CEO
    Transaction
    Open-market saleAs filed: “S”
    Asset
    GILEAD SCIENCES, INC.
    Ticker
    GILD
    Shares
    115.6K
    Price per share
    $135
    Value
    $15,611,400
    Execution date (reported)
    Jan 23, 2026
    Owned after transaction
    566.7K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    3

    Calculation

    Value = shares × reported price per share

    • Shares: 115.6K
    • Price: $135

    = $15,611,400

    What this establishes

    O'Day Daniel Patrick filed this Form 4 reporting a open-market sale of GILD on Jan 23, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chairman & CEO
    O'Day Daniel Patrickcik:0001638643
    Issuer
    GILEAD SCIENCES, INC.cik:0000882095

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.